drugset

drugset / Trial / NCT03748186

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186 ↗

Phase 1 Completed 136 enrolled Sutro Biopharma, Inc.

NaSequentialOpen-labelTreatment

Summary

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Timeline

Start: 2019-02-01
Primary completion: 2024-06-04
Completion: 2024-06-04

Publications

Li X, Zhou S, Abrahams CL, Krimm S, Smith J, Bajjuri K, Stephenson HT, Henningsen R, Hanson J, Heibeck TH, Calarese D, Tran C, Yin G, Stafford RL, Yam AY, Kline T, De Almeida VI, Sato AK, Lupher M, Bedard K, Hallam TJ. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167. doi: 10.1158/1535-7163.MCT-22-0322.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Luveltamab tazevibulin	Monoclonal antibody	4.3 mg/kg	Intravenous
Subject	Luveltamab tazevibulin	Monoclonal antibody	5.2 mg/kg	Intravenous

Indications